Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...

The drug for which spending increased the most due to a price increase was Gilead’s HIV treatment Biktarvy. The company ...

Mizuho Securities analyst Salim Syed has assigned their bullish stance on GILD stock, giving a Buy rating yesterday.Pick the best stocks and ...

Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a ...

Alonzo Liñán, Keller’s public works director, said at the Keller City Council meeting Dec. 9 that the design of the Mt.

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

Shares of Gilead Sciences Inc. GILD inched 0.04% higher to $92.38 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.82% to 6 ...

Two friends are taking on a mission assist families that have been affected by domestic violence homicides. Dr. Cheryl ...

Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...

Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...